Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 Return-on-Tangible-Asset is 0.39% as of Sep. 2025, which is 91% below its 10-year median of 4.30. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Sai Parenteral's ranks worse than 62.7% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sai Parenteral's's annualizedNet Income for the quarter that ended in Sep. 2025 was ₹33 Mil. Sai Parenteral's's average total tangible assets for the quarter that ended in Sep. 2025 was ₹8,499 Mil. Therefore, Sai Parenteral's's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2025 was 0.39%.
The historical rank and industry rank for Sai Parenteral's's Return-on-Tangible-Asset or its related term are showing as below:
NSE:SAIPARENT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.19 Med: 4.3 Max: 4.7
Current: 0.19
During the past 3 years, Sai Parenteral's's highest Return-on-Tangible-Asset was 4.70%. The lowest was 0.19%. And the median was 4.30%.
NSE:SAIPARENT's Return-on-Tangible-Asset is ranked worse than 62.7% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.015
vs NSE:SAIPARENT: 0.19
Sai Parenteral's (NSE:SAIPARENT) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sai Parenteral's Return-on-Tangible-Asset Related Terms
Sai Parenteral's Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Return-on-Tangible-Asset Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
Return-on-Tangible-Asset
3.29
4.30
4.70
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Return-on-Tangible-Asset
0.00
0.00
0.00
0.39
NSE:SAIPARENT vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Sep. 2025) net income data.
What does a Return-on-Tangible-Asset of 0.39% mean?
Sai Parenteral's (NSE:SAIPARENT) has a Return-on-Tangible-Asset of 0.39% as of Sep. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sai Parenteral's and its competitors. This is 91% below median its historical median of 4.30. Over the past decade, Sai Parenteral's' Return-on-Tangible-Asset has ranged from 0.19 to 4.70. According to the industry distribution chart, Sai Parenteral's ranks #632 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 62.7%.
Is Sai Parenteral's' Return-on-Tangible-Asset too high?
Sai Parenteral's' current Return-on-Tangible-Asset of 0.39% is 91% below median its 10-year median of 4.30. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 4.70. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.02. Sai Parenteral's' value of 0.39% is 87.1% below this industry median. Based on the distribution chart, Sai Parenteral's ranks #632 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #632 out of 1008 companies for Return-on-Tangible-Asset. This places Sai Parenteral's in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.02. Sai Parenteral's' value of 0.39% is 87.1% below this benchmark. Historically, Sai Parenteral's' own Return-on-Tangible-Asset has ranged from 0.19 to 4.70 over the past decade. While the company's 10-year median is 4.30 vs. the industry median of 3.02, Sai Parenteral's has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.02, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current Return-on-Tangible-Asset of 0.39% is 87.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current Return-on-Tangible-Asset is 0.39%, which is 91% below median its own 10-year median of 4.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Return-on-Tangible-Asset of 0.39%. The current Return-on-Tangible-Asset is 0.39%, which is 91% below median its 10-year median of 4.30 and 87.1% below the Drug Manufacturers industry median of 3.02. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Return-on-Tangible-Asset is 0.39% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
